Cellceutix chief scientific officer Krishna Menon said to date, everything is completed and Cellceutix is waiting for the host hospitals to begin dosing patients, which the company anticipates will happen shortly, but it is in the hospitals’ hands at the point.
"Dana-Farber is one of the few hospitals in the world that collects data ‘mapping’ the human genome as related to tumor profiling and the information that will be collected from our clinical trials of Kevetrin™ could prove an invaluable asset to those suffering from cancer and to Cellceutix," Menon added.
Kevetrin is an anti cancer drug that uses both wild and mutant types of p53,which is produced by Cellceutix.